EQS: latest releases

• Hamburg, November 30, 2021 - Aves One AG, a portfolio holder of long-lived rail assets, looks back on a successful first nine months of fiscal year 2021.
• Thanks to a strong development of the core business "Rail", sales as well as operating profit were increased.
• Consolidated sales in the first nine months increased slightly to EUR 76.6 million (previous year: EUR 75.5 million).
• "As in the previous year, the first nine months of 2021 have been impacted by the effects of the COVID 19 pandemic.

• Following approval by the German Federal Financial Supervisory Authority (Bundesanstalt fr Finanzdienstleistungsaufsicht, "BaFin"), Brockhaus Technologies has today closed the acquisition of Bikeleasing, thus adding another company to the technology group.
• Established in 2015, Bikeleasing is one of the leading digital platforms for the highly automated facilitation and management of B2B leasing contracts.
• Through its platform, Bikeleasing currently allows over 30,000 corporate customers of the German Mittelstand to offer company bicycle leases to their more than 1.6 million employees.
• As innovation leader, Bikeleasing has since its foundation recorded strong and highly profitable growth while continuously increasing its market share.

• Paris, November 30, 2021 - Bilendi, a European leader in research technology and data, announces the completion of the acquisition of the respondi Group following the fulfilment of the customary closing conditions.
• With this strategic move, Bilendi takes a significant step forward in its development and further strengthens its position in the top three European markets: Germany, France and the United Kingdom.
• Founded in 2005 in Cologne, Germany, respondi is a European player dedicated to data collection for market research in Europe.
• Following the acquisition of respondi, Bilendi will succeed in its target to achieve annual revenues of 50 million by 2023, on a pro forma basis [1] .

• Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
• The issuer is solely responsible for the content of this announcement.
• Custodian REIT (LSE: CREI), the UK property investment company, announces that at 30 November 2021 the Company's capital consists of 440,850,398 ordinary shares with voting rights.
• Therefore, the total number of voting rights in the Company at 30 November 2021 is 440,850,398.

• Form 8.3 - The Vanguard Group, Inc.: Equiniti Group plc
  Dissemination of a Regulatory Announcement, transmitted by EQS Group.
• The issuer is solely responsible for the content of this announcement.
• (a) Full name of discloser:
  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
  The naming of nominee or vehicle companies is insufficient.
• For a trust, the trustee(s), settlor and beneficiaries must be named.

• Form 8.3 - The Vanguard Group, Inc.: National Express Group plc
  Dissemination of a Regulatory Announcement, transmitted by EQS Group.
• The issuer is solely responsible for the content of this announcement.
• (a) Full name of discloser:
  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
  The naming of nominee or vehicle companies is insufficient.
• For a trust, the trustee(s), settlor and beneficiaries must be named.

• Garbsen, November 30, 2021 - Technology company LPKF today opened a bio lab for a technology platform for single cell analysis at the company's headquarters in Garbsen, Germany.
• Now LPKF has developed a platform that will enable future customers in the biotechnology and pharmaceutical industries to perform single-cell screenings quickly and efficiently.
• ARRALYZE combines biomedical research with software and precision technology and is designed to accelerate the development of personalized medicine, e.g.
• LPKF Laser & Electronics AG is a leading supplier of laser-based solutions for the technology industry.

• Form 8.3 - The Vanguard Group, Inc.: Vivo Energy plc
  Dissemination of a Regulatory Announcement, transmitted by EQS Group.
• The issuer is solely responsible for the content of this announcement.
• (a) Full name of discloser:
  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
  The naming of nominee or vehicle companies is insufficient.
• For a trust, the trustee(s), settlor and beneficiaries must be named.

• Form 8.3 - The Vanguard Group, Inc.: Avast plc
  Dissemination of a Regulatory Announcement, transmitted by EQS Group.
• The issuer is solely responsible for the content of this announcement.
• (a) Full name of discloser:
  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
  The naming of nominee or vehicle companies is insufficient.
• For a trust, the trustee(s), settlor and beneficiaries must be named.

• Media and Games Invest: Official rollout of advertising targeting solution ATOM: strong performance of 28% higher click-through-rates and app 15% better monetization compared to campaigns without IDFA
  The issuer is solely responsible for the content of this announcement.
• Media and Games Invest: Official rollout of advertising targeting solution ATOM: strong performance of 28% higher click-through-rates and app 15% better monetization compared to campaigns without IDFA
  Verve Group's in-house developed advertising targeting solution ATOM achieves a level of effectiveness that currently cannot be matched by any other provider without the use of IDFA.
• Largest German private media agency Pilot is committed for broad rollout to its customers.
• With every step we're inching closer to successfully address one of the biggest challenges in the advertising industry."

• Form 8.3 - The Vanguard Group, Inc.: Sanne Group plc
  Dissemination of a Regulatory Announcement, transmitted by EQS Group.
• The issuer is solely responsible for the content of this announcement.
• (a) Full name of discloser:
  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
  The naming of nominee or vehicle companies is insufficient.
• For a trust, the trustee(s), settlor and beneficiaries must be named.

• Form 8.3 - The Vanguard Group, Inc.: Playtech plc
  Dissemination of a Regulatory Announcement, transmitted by EQS Group.
• The issuer is solely responsible for the content of this announcement.
• (a) Full name of discloser:
  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
  The naming of nominee or vehicle companies is insufficient.
• For a trust, the trustee(s), settlor and beneficiaries must be named.

• Berlin-based crypto consultancy F5 Crypto Capital is enabling qualified investors to invest in the crypto market through its subsidiary F5 Crypto Management GmbH.
• The F5 Crypto Fonds 1 aims for high diversification through targeted selection of crypto assets.
• F5 Crypto Fund 1 offers weekly subscription and redemption, and shares can be booked into the investor's custody account.
• The F5 Crypto Fund 1 paves the way for diversified investing in the crypto market and increases the confidence of Europe's institutional investors in the new asset class cryptocurrencies.

Chelverton UK Dividend Trust plc: Net Asset Value(s)
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
The Net Asset Value (NAV) at 29/11/2021 was:
Number of shares in issue:

• The core business of BluCon Biotech GmbH is a primary focus of the Federal Ministry of Economics funding program, which advances the industrial bioeconomy.
• The program promotes the implementation of innovative processes on an industrial scale and the transfer of bioeconomic products and processes into industrial practice.
• BluCon Biotech GmbH provides a unique technology by which L-lactic acid can be produced at lowest possible production costs.
• Besides developing BluCon technology to commercial stage, BluCon Biotech GmbH serves as a platform to acquire and develop further technologies in the field of applied biotechnology.